feng zhang brought $ 160 million early days analyst tells technology transformative companies fact single deal valued potential $ 2.6 billion tells overall size technology reach says anette breindl senior science editor thomson reuters bioworld commercial potential crispr not lost astrazeneca believes technology offers powerful solution research development challenges plague pharmaceutical industry says company spokeswoman karen birmingham accelerating identification validation novel therapeutic targets creating better animal models human diseases shorter time frame reducing number failed products crispr looks set shave millions r&d costs boost drug discovery says ultimately application crispr hope increase productivity pharmaceutical r&d process likewise agricultural space crispr